The DOI matches its Crossref record.
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017
Open accessAbstract
BACKGROUND: Increased pathologic complete response (pCR) rates observed with neoadjuvant chemotherapy (NCT) for some subsets of patients with invasive breast cancer have prompted interest in whether patients who achieved a pCR can be identified preoperatively and potentially spared the morbidity of surgery. The objective of this multicenter, retrospective study was to estimate the accuracy of preoperative magnetic resonance imaging (MRI) in predicting a pCR in the breast. METHODS: MRI studies at baseline and after the completion of NCT plus data regarding pathologic response were collected retrospectively from 746 women who received treatment at 8 institutions between 2002 and 2011. Tumors were characterized by immunohistochemical phenotype into 4 categories based on receptor expression: hormone (estrogen and progesterone) receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative (n = 327), HR‐positive/HER2‐positive, (n = 148), HR‐negative/HER2‐positive, (n = 101), and triple‐negative (HR‐negative/HER2 negative; n = 155). In all, 194 of 249 patients (78%) with HER2‐positive tumors received trastuzumab. Univariate and multivariate analyses of factors associated with radiographic complete response (rCR) and pCR were performed. RESULT: For the total group, the rCR and pCR rates were 182 of 746 patients (24%) and 179 of 746 patients (24%), respectively, and the highest pCR rate was observed for the triple‐negative subtype (57 of 155 patients; 37%) and the HER2‐positive subtype (38 of 101 patients; 38%). The overall accuracy of MRI for predicting pCR was 74%. The variables sensitivity, negative predictive value, positive predictive value, and accuracy differed significantly among tumor subtypes, and the greatest negative predictive value was observed in the triple‐negative (60%) and HER2‐positive (62%) subtypes. CONCLUSIONS: The overall accuracy of MRI for predicting pCR in invasive breast cancer patients who were receiving NCT was 74%. The performance of MRI differed between subtypes, possibly influenced by differences in pCR rates between groups. Future studies will determine whether MRI in combination with directed core biopsy improves the predictive value of MRI for pathologic response. Cancer 2013. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer
Kuhl, C. K., Strobel, K., Bieling, H., Leutner, C., Schild, H. H., & Schrading, S. (2017) · Radiology · doi:10.1148/radiol.2016161444 · Cited by 350
Gu, Y.-L., Pan, S.-M., Ren, J., Yang, Z.-X., & Jiang, G.-Q. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.010 · Cited by 128
Metadata
- Authors
- De Los Santos, J. F., Cantor, A., Amos, K. D., Forero, A., Golshan, M., Horton, J. K., Hudis, C. A., Hylton, N. M., McGuire, K., Meric‐Bernstam, F., Meszoely, I. M., Nanda, R., & Hwang, E. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-02-21
- Volume
- 119
- Issue
- 10
- Pages
- 1776-1783
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1551111627
- Cited by
- 201
- References
- 0
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. https://app.cochat.ai/papers/10.1002/cncr.27995
- The paper
- De Los Santos, J. F., Cantor, A., Amos, K. D., Forero, A., Golshan, M., Horton, J. K., Hudis, C. A., Hylton, N. M., McGuire, K., Meric‐Bernstam, F., Meszoely, I. M., Nanda, R., & Hwang, E. S. (2013). Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. https://doi.org/10.1002/cncr.27995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.